Squalamine Analogs Reducing Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural squalamine, with its antiangiogenic and antimicrobial properties, is limited in supply and has high cytotoxicity, while its synthetic analogs exhibit reduced activity against certain Gram-negative bacteria like E. coli and high cytotoxicity.
Innovation Solution
Development of squalamine analogs with specific structural modifications, such as compounds of formula (I), which balance antibacterial activity against both Gram-positive and Gram-negative bacteria while reducing cytotoxicity, including the use of stereoisomers and pharmaceutically acceptable salts, for treatment of infections and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If synthetic analogs of squalamine are used to overcome limited natural supply, then availability is improved, but cytotoxicity increases and antibacterial activity against Gram-negative bacteria decreases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the polyamine chain structure (formula II) including varying chain length, branching patterns, and terminal groups to optimize the balance between antibacterial activity and cytotoxicity. This structural parameter optimization allows synthetic analogs to maintain availability while reducing harmful cytotoxic effects compared to previous derivatives.
Solution Approach 2:
The invention creates composite molecular structures combining the cholestane backbone with optimized polyamine chains (formulae IIa-IIi) to achieve a synergistic effect where the amphiphilic nature of the molecule provides both membrane-disrupting antibacterial activity and reduced mammalian cell toxicity through controlled hydrophilicity-hydrophobicity balance.
2Object-affected harmful factors
If synthetic analogs with modified polyamine chains are developed to reduce cytotoxicity, then cytotoxicity is improved, but antibacterial activity against Gram-negative bacteria worsens
Solution Approach 1:
The patent resolves this contradiction through precise parameter changes in the polyamine chain structure, specifically optimizing the balance between chain length, degree of substitution, and terminal group functionality. The formula II derivatives demonstrate that controlled modification of these parameters can simultaneously reduce cytotoxicity while maintaining or enhancing activity against Gram-negative bacteria like E. coli, contrary to previous derivatives.
Solution Approach 2:
The invention applies local quality by introducing specific functional groups at terminal positions of the polyamine chain (formulae IIa-IIi) that locally enhance interaction with Gram-negative bacterial membranes through targeted electrostatic and hydrophobic interactions, while the overall molecular architecture maintains reduced cytotoxicity.
3Adaptability or versatility
If existing squalamine derivatives are used for treatment, then treatment options are improved, but activity against multiresistant bacteria is insufficient
Solution Approach 1:
The patent addresses multidrug resistance through parameter changes in the polyamine chain structure (formulae IIa-IIi) that enable these derivatives to bypass resistance mechanisms. The modified structures interact with bacterial membranes and intracellular targets through mechanisms distinct from conventional antibiotics, thereby maintaining effectiveness against multiresistant Gram-positive and Gram-negative bacteria while expanding treatment options.
Solution Approach 2:
The invention converts the amphiphilic nature of squalamine derivatives, which initially contributed to cytotoxicity, into a beneficial mechanism for penetrating and disrupting bacterial membranes. The hydrophobic cholestane backbone and hydrophilic polyamine chain work synergistically to target bacterial cell membranes specifically, converting a previously harmful property into a selective therapeutic advantage against resistant bacteria.
Data Source
AI summary
The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.